Previous Close | 139.10 |
Open | 139.25 |
Bid | 136.01 x 800 |
Ask | 140.50 x 800 |
Day's Range | 138.57 - 141.76 |
52 Week Range | 89.04 - 143.35 |
Volume | |
Avg. Volume | 845,978 |
Market Cap | 13.875B |
Beta (5Y Monthly) | 0.24 |
PE Ratio (TTM) | 56.45 |
EPS (TTM) | 2.47 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 29, 1995 |
1y Target Est | 151.20 |
Subscribe to Yahoo Finance Plus to view Fair Value for NBIX
Artificial intelligence plays HubSpot and Arista Networks are among five stocks near buy points with big market news on tap.
Neurocrine Biosciences Inc (NASDAQ:NBIX), a company specializing in the development of treatments for neurological and endocrine-related diseases and disorders, has reported an insider sale according to a recent SEC filing.
Director Richard Pops has sold 23,200 shares of Neurocrine Biosciences Inc (NASDAQ:NBIX) on March 13, 2024, according to a recent SEC filing.